Use of remdesivir for patients with Covid-19: a review article
SUMMARY The etiological agent of COVID-19, which causes severe respiratory diseases such as pneumonia and pulmonary insufficiency, has been confirmed as a new coronavirus, now known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is currently no authorized medication for the treatment of COVID-19. No vaccines have been authorized. Thus, this study aimed at conducting a review of the use of Remdesivir in patients with COVID-19. The following electronic databases were used MEDLINE, SCIELO, LILACS, and PUBMED. On May 1, Remdesivir received emergency use authorization from the Food and Drug Administration. Remdesivir is currently the most promising molecule in the treatment of COVID-19, taking into account its broad antiviral spectrum (considering the genetic sequences of the virus, it is expected to maintain activity against SARS-CoV-2). There is in vitro and in vivo information available for coronaviruses, as well as an extensive clinical safety database (from a clinical trial of the Ebola virus and in the context of the Monitored Emergency Use of Unregistered and Investigational Interventions - MEURI). Further studies are relevant as available data on the efficacy and safety of Remdesivir against SARS-nCoV-2 are limited.
Main Authors: | , , , , , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Médica Brasileira
2020
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020000600838 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0104-42302020000600838 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0104-423020200006008382020-07-17Use of remdesivir for patients with Covid-19: a review articleAzevedo,Thomás Cavalcanti Pires deAzevedo,Pedro Cavalcanti Pires deSilveira Filho,Robson NatarioCarvalho,Arthur Ricardo Vilar Scavuzzi deCezarotti Filho,Murilo LoboBarbosa,Fabiano TimbóSousa-Rodrigues,Célio Fernando deMatos-Rocha,Thiago JoséRamos,Fernando Wagner da Silva Betacoronavirus Coronavirus Infections/therapy Coronavirus SUMMARY The etiological agent of COVID-19, which causes severe respiratory diseases such as pneumonia and pulmonary insufficiency, has been confirmed as a new coronavirus, now known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is currently no authorized medication for the treatment of COVID-19. No vaccines have been authorized. Thus, this study aimed at conducting a review of the use of Remdesivir in patients with COVID-19. The following electronic databases were used MEDLINE, SCIELO, LILACS, and PUBMED. On May 1, Remdesivir received emergency use authorization from the Food and Drug Administration. Remdesivir is currently the most promising molecule in the treatment of COVID-19, taking into account its broad antiviral spectrum (considering the genetic sequences of the virus, it is expected to maintain activity against SARS-CoV-2). There is in vitro and in vivo information available for coronaviruses, as well as an extensive clinical safety database (from a clinical trial of the Ebola virus and in the context of the Monitored Emergency Use of Unregistered and Investigational Interventions - MEURI). Further studies are relevant as available data on the efficacy and safety of Remdesivir against SARS-nCoV-2 are limited.info:eu-repo/semantics/openAccessAssociação Médica BrasileiraRevista da Associação Médica Brasileira v.66 n.6 20202020-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020000600838en10.1590/1806-9282.66.6.838 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Azevedo,Thomás Cavalcanti Pires de Azevedo,Pedro Cavalcanti Pires de Silveira Filho,Robson Natario Carvalho,Arthur Ricardo Vilar Scavuzzi de Cezarotti Filho,Murilo Lobo Barbosa,Fabiano Timbó Sousa-Rodrigues,Célio Fernando de Matos-Rocha,Thiago José Ramos,Fernando Wagner da Silva |
spellingShingle |
Azevedo,Thomás Cavalcanti Pires de Azevedo,Pedro Cavalcanti Pires de Silveira Filho,Robson Natario Carvalho,Arthur Ricardo Vilar Scavuzzi de Cezarotti Filho,Murilo Lobo Barbosa,Fabiano Timbó Sousa-Rodrigues,Célio Fernando de Matos-Rocha,Thiago José Ramos,Fernando Wagner da Silva Use of remdesivir for patients with Covid-19: a review article |
author_facet |
Azevedo,Thomás Cavalcanti Pires de Azevedo,Pedro Cavalcanti Pires de Silveira Filho,Robson Natario Carvalho,Arthur Ricardo Vilar Scavuzzi de Cezarotti Filho,Murilo Lobo Barbosa,Fabiano Timbó Sousa-Rodrigues,Célio Fernando de Matos-Rocha,Thiago José Ramos,Fernando Wagner da Silva |
author_sort |
Azevedo,Thomás Cavalcanti Pires de |
title |
Use of remdesivir for patients with Covid-19: a review article |
title_short |
Use of remdesivir for patients with Covid-19: a review article |
title_full |
Use of remdesivir for patients with Covid-19: a review article |
title_fullStr |
Use of remdesivir for patients with Covid-19: a review article |
title_full_unstemmed |
Use of remdesivir for patients with Covid-19: a review article |
title_sort |
use of remdesivir for patients with covid-19: a review article |
description |
SUMMARY The etiological agent of COVID-19, which causes severe respiratory diseases such as pneumonia and pulmonary insufficiency, has been confirmed as a new coronavirus, now known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is currently no authorized medication for the treatment of COVID-19. No vaccines have been authorized. Thus, this study aimed at conducting a review of the use of Remdesivir in patients with COVID-19. The following electronic databases were used MEDLINE, SCIELO, LILACS, and PUBMED. On May 1, Remdesivir received emergency use authorization from the Food and Drug Administration. Remdesivir is currently the most promising molecule in the treatment of COVID-19, taking into account its broad antiviral spectrum (considering the genetic sequences of the virus, it is expected to maintain activity against SARS-CoV-2). There is in vitro and in vivo information available for coronaviruses, as well as an extensive clinical safety database (from a clinical trial of the Ebola virus and in the context of the Monitored Emergency Use of Unregistered and Investigational Interventions - MEURI). Further studies are relevant as available data on the efficacy and safety of Remdesivir against SARS-nCoV-2 are limited. |
publisher |
Associação Médica Brasileira |
publishDate |
2020 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302020000600838 |
work_keys_str_mv |
AT azevedothomascavalcantipiresde useofremdesivirforpatientswithcovid19areviewarticle AT azevedopedrocavalcantipiresde useofremdesivirforpatientswithcovid19areviewarticle AT silveirafilhorobsonnatario useofremdesivirforpatientswithcovid19areviewarticle AT carvalhoarthurricardovilarscavuzzide useofremdesivirforpatientswithcovid19areviewarticle AT cezarottifilhomurilolobo useofremdesivirforpatientswithcovid19areviewarticle AT barbosafabianotimbo useofremdesivirforpatientswithcovid19areviewarticle AT sousarodriguesceliofernandode useofremdesivirforpatientswithcovid19areviewarticle AT matosrochathiagojose useofremdesivirforpatientswithcovid19areviewarticle AT ramosfernandowagnerdasilva useofremdesivirforpatientswithcovid19areviewarticle |
_version_ |
1756410068636532736 |